drugset / Trial / NCT04326790

The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention

NCT04326790

Phase 2 Terminated 105 enrolled National and Kapodistrian University of Athens
RandomizedParallel-groupOpen-labelTreatment

Summary

Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question arises whether colchicine, administered in a relatively low dose, could potentially have an effect the patients' clinical course by limiting the myocardial necrosis and pneumonia development in the context of COVID-19. If present, this effect would be attributed to its potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2 endocytosis in myocardial and endothelial respiratory cells.

Timeline

Start
2020-04-03
Primary completion
2020-04-27
Completion
2020-04-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg

Indications